Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China flag China · Delayed Price · Currency is CNY
13.82
+0.21 (1.54%)
Oct 30, 2026, 3:00 PM CST

SHA:600535 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
970.021,4362,9944,4513,1192,304
Short-Term Investments
-1,404----
Trading Asset Securities
2,7301,394524.72300.711,1251,487
Cash & Short-Term Investments
3,7004,2343,5184,7514,2443,791
Cash Growth
6.04%20.34%-25.95%11.95%11.95%78.94%
Accounts Receivable
2,7752,4181,9662,1313,3483,796
Other Receivables
50.7139.9623.0611.498.989.47
Receivables
2,8262,4581,9892,1423,3573,805
Inventory
1,3831,4271,7121,7481,5321,548
Other Current Assets
150.03111.591.7291.43127.08105
Total Current Assets
8,0598,2307,3118,7339,2609,249
Property, Plant & Equipment
3,4243,5463,6483,7693,8834,088
Long-Term Investments
1,2131,3461,8212,0541,5111,229
Goodwill
---15.8815.88167.08
Other Intangible Assets
795.91794.39604.17573.64459.43474.54
Long-Term Deferred Tax Assets
73.0167.0553.175088.2960.79
Long-Term Deferred Charges
1,2701,3331,4661,4761,1571,193
Other Long-Term Assets
230.4922.6672.5443.14102.0879.68
Total Assets
15,06515,34014,97616,71416,47716,542

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
425.89376.9606.81572.73887.77728.58
Accrued Expenses
355.54537.57171.05178.38242.79213.15
Short-Term Debt
1.911,116699.54814.63201.77188.79
Current Portion of Long-Term Debt
35.324.96586.83462.74475.21343.33
Current Portion of Leases
-49.747.8458.5453.9855.67
Current Income Taxes Payable
161.15110.9157.7818.0484.62108.09
Current Unearned Revenue
53.6149.8869.8591.6292.3568.33
Other Current Liabilities
623.6762.39109.98172.88108.72149.12
Total Current Liabilities
1,6572,3082,3502,3702,1471,855
Long-Term Debt
111.05216.87253.761,4141,3761,034
Long-Term Leases
34.1651.1967.9781.5275.3181.63
Long-Term Unearned Revenue
204.53189.95193.29159.02177.79214.57
Long-Term Deferred Tax Liabilities
15.5926.020.40.1122.8742.18
Total Liabilities
2,0222,7922,8654,0243,7993,228

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
1,4941,4941,4941,5001,5001,513
Additional Paid-In Capital
483.47482.39458.96958.081,4571,530
Retained Earnings
10,98510,3919,8989,9299,35110,222
Treasury Stock
----105.98-105.98-251.29
Comprehensive Income & Other
-43.9437.2452.2288211.58-32.19
Total Common Equity
12,91912,40411,90312,36812,41212,981
Minority Interest
124.07143.49207.86321.59265.12332.56
Shareholders' Equity
13,04312,54812,11112,69012,67813,314
Total Liabilities & Equity
15,06515,34014,97616,71416,47716,542

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
182.431,4381,6562,8312,1821,704
Net Cash (Debt)
3,5172,7951,8621,9202,0622,088
Net Cash Growth
33.64%50.10%-2.99%-6.89%-1.23%-
Net Cash Per Share
2.361.871.251.291.401.39
Filing Date Shares Outstanding
1,4941,4941,4941,4941,4941,499
Total Common Shares Outstanding
1,4941,4941,4941,4941,4941,499
Working Capital
6,4025,9224,9616,3637,1137,394
Book Value Per Share
8.658.307.978.288.318.66
Tangible Book Value
12,12311,61011,29911,77911,93712,340
Tangible Book Value Per Share
8.117.777.567.887.998.23
Buildings
-3,5293,5173,5053,4903,398
Machinery
-3,8033,7633,6253,4723,340
Construction In Progress
-322.42221.76153.87102.96167.85